Australia begins trials for a brain implant enabling ALS patients to control smartphones with thought, marking a significant advancement in BCI technology.
In Melbourne, Australia, groundbreaking trials have begun for a brain implant designed to enable patients with ALS to control smartphones through thought alone. The Stentrode neurointerface, created by Synchron, interprets brain activity linked to movement, allowing users to perform actions on devices like moving a cursor.
Surgical procedures for this pioneering trial are scheduled to start in April, marking a significant milestone in the field of brain-computer interfaces (BCIs). Peter Mitchell, a lead researcher, emphasized the unprecedented nature of this technology, stating, "Transforming nerve impulses into actions in the external world simply by thought— I can't recall anything this advanced in neuroscience."
Synchron stands out as the only company globally that has successfully implanted a BCI into a human brain via blood vessels, a method that is less invasive than conventional open-brain surgery. The current study, named FOCUS-AU, aims to recruit 10 ALS patients for trials across several hospitals, including the Royal Melbourne Hospital.
Mechanism of the Implant
The Stentrode implant comprises three main components: tiny electrodes for capturing brain activity, a small device positioned near the collarbone, and a thin connecting cable. Synchron's CEO, Tom Oxley, described how the electrodes function like antennas, gently inserted through the neck into the brain's motor cortex.
The device processes brain signals, translating them into actions. For example, when a paralyzed individual attempts to move their hand, the system sends a corresponding signal. Oxley noted that while initial control requires conscious effort, it will eventually feel more intuitive. "This way, people with paralysis or limited mobility can independently control devices without intermediaries," he added.
Global Context of BCI Development
In comparison, Neuralink, founded by Elon Musk, has made headlines with its rapid advancements, including a recent case where a patient learned to control a computer cursor within minutes of surgery. The Chinese BCI startup NeuCyber Neurotech, however, acknowledges that it trails Neuralink by approximately three years in development. Their Beinao-2 implant, currently in animal trials, aims to integrate fully with the brain.
Despite the competitive landscape, China's emphasis on neurotechnology is evident, as its government has included BCI in its strategic industries for future development, alongside sectors like AI and quantum computing.
